SCYNEXIS (NASDAQ:SCYX) Share Price Passes Below 200-Day Moving Average – Should You Sell?

SCYNEXIS, Inc. (NASDAQ:SCYXGet Free Report) crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $1.49 and traded as low as $1.11. SCYNEXIS shares last traded at $1.12, with a volume of 112,390 shares changing hands.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised shares of SCYNEXIS from a “sell” rating to a “hold” rating in a report on Friday, November 8th.

View Our Latest Report on SCYNEXIS

SCYNEXIS Stock Performance

The company has a market capitalization of $42.50 million, a price-to-earnings ratio of -1.51 and a beta of 1.53. The stock’s fifty day simple moving average is $1.19 and its two-hundred day simple moving average is $1.49.

SCYNEXIS (NASDAQ:SCYXGet Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.14. The firm had revenue of $0.66 million for the quarter. SCYNEXIS had a negative return on equity of 66.21% and a negative net margin of 425.41%.

Institutional Trading of SCYNEXIS

A hedge fund recently bought a new stake in SCYNEXIS stock. XTX Topco Ltd acquired a new position in shares of SCYNEXIS, Inc. (NASDAQ:SCYXFree Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 17,111 shares of the company’s stock, valued at approximately $25,000. Institutional investors and hedge funds own 54.37% of the company’s stock.

About SCYNEXIS

(Get Free Report)

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.

See Also

Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.